Everest Medicines Limited (HKG: 1952)
Hong Kong
· Delayed Price · Currency is HKD 25.20
-2.10 (-7.69%)
Oct 9, 2024, 4:08 PM HKT
Everest Medicines Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 418.55 | 125.93 | 12.79 | 0.05 | - | - | Upgrade
|
| Revenue Growth (YoY) | 1927.58% | 884.46% | 23588.89% | - | - | - | Upgrade
|
| Cost of Revenue | 101.53 | 34.41 | 4.65 | 0.02 | - | - | Upgrade
|
| Gross Profit | 317.02 | 91.52 | 8.15 | 0.03 | - | - | Upgrade
|
| Selling, General & Admin | 536.7 | 396.57 | 603.23 | 440.83 | 311.08 | 55.04 | Upgrade
|
| Research & Development | 504.73 | 540.05 | 809.74 | 613.43 | 377.41 | 150.89 | Upgrade
|
| Other Operating Expenses | 319.69 | 6.16 | -0.12 | -4.96 | -0.98 | -7.41 | Upgrade
|
| Operating Expenses | 1,361 | 942.78 | 1,413 | 1,049 | 687.51 | 198.52 | Upgrade
|
| Operating Income | -1,044 | -851.27 | -1,405 | -1,049 | -687.51 | -198.52 | Upgrade
|
| Interest Expense | -23.06 | -23.06 | -5.59 | -4.81 | -33.87 | -2 | Upgrade
|
| Interest & Investment Income | 87.14 | 107.67 | 38.48 | 28.88 | 2.04 | 0.06 | Upgrade
|
| Currency Exchange Gain (Loss) | -28.07 | -28.07 | -155.18 | 22.94 | -0.85 | -0.63 | Upgrade
|
| Other Non Operating Income (Expenses) | 7.38 | 2.82 | -1.61 | -6.46 | -4,938 | -36.45 | Upgrade
|
| EBT Excluding Unusual Items | -1,001 | -791.91 | -1,529 | -1,009 | -5,658 | -237.55 | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.85 | 0.85 | -21.75 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -1.43 | -1.43 | 1,320 | - | - | - | Upgrade
|
| Asset Writedown | -51.97 | -51.97 | -16.49 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 23.04 | Upgrade
|
| Pretax Income | -1,053 | -844.46 | -247.28 | -1,009 | -5,658 | -214.51 | Upgrade
|
| Income Tax Expense | - | - | 0.01 | - | - | - | Upgrade
|
| Net Income | -1,053 | -844.46 | -247.28 | -1,009 | -5,658 | -214.51 | Upgrade
|
| Net Income to Common | -1,053 | -844.46 | -247.28 | -1,009 | -5,658 | -214.51 | Upgrade
|
| Shares Outstanding (Basic) | - | 313 | 298 | 293 | 85 | 5 | Upgrade
|
| Shares Outstanding (Diluted) | - | 313 | 298 | 293 | 85 | 5 | Upgrade
|
| Shares Change (YoY) | - | 5.18% | 1.49% | 243.61% | 1532.82% | 283.16% | Upgrade
|
| EPS (Basic) | - | -2.70 | -0.83 | -3.44 | -66.29 | -41.04 | Upgrade
|
| EPS (Diluted) | - | -2.70 | -0.83 | -3.44 | -66.29 | -41.04 | Upgrade
|
| Free Cash Flow | - | -886.53 | -1,512 | -839.89 | -480.5 | -95.74 | Upgrade
|
| Free Cash Flow Per Share | - | -2.83 | -5.08 | -2.86 | -5.63 | -18.32 | Upgrade
|
| Gross Margin | 75.74% | 72.67% | 63.69% | 57.41% | - | - | Upgrade
|
| Operating Margin | -249.45% | -675.97% | -10981.12% | -1943096.30% | - | - | Upgrade
|
| Profit Margin | -251.64% | -670.57% | -1933.11% | -1867998.15% | - | - | Upgrade
|
| Free Cash Flow Margin | - | -703.97% | -11817.36% | -1555344.44% | - | - | Upgrade
|
| EBITDA | -994.99 | -804.84 | -1,391 | -1,043 | -683.03 | -195.73 | Upgrade
|
| D&A For EBITDA | 49.11 | 46.42 | 13.81 | 6.21 | 4.48 | 2.8 | Upgrade
|
| EBIT | -1,044 | -851.27 | -1,405 | -1,049 | -687.51 | -198.52 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.